medigraphic.com
Colegio de Medicina Interna de México.

2015, Number 1

<< Back Next >>

Med Int Mex 2015; 31 (1)

Where art and science join: contrast media induced nephropathy and its risk factors

Bastida-Alquicira J, Motta-Ramírez GA, Amezquita-Pérez S, Gómez-Vázquez JA

Language: Spanish
References: 37
Page: 64-76
PDF size: 449.18 Kb.


ABSTRACT

Contrast media induced nephropathy (CIN) is attributed to several factors: the use of hyperosmolar contrast media, the number of studies with contrast especially if intra-arterial, diseases that decrease renal perfusion per se, as diabetes and hypertension, and the use of nephrotoxic drugs, among others. Current literature was review seeking review studies on the radiological contrasts pathogenesis of adverse reactions, associated event types, risk groups, diagnosis and conduct to follow. Contrast media have been considered the main cause of renal disease in hospitalized patients, not forgetting the outpatient. In most recent research study of contrast media induced nephropathy, this is overdiagnosed and confused of associated nephrotoxic effects that determine events. However, there is evidence that at least in patients with severe renal impairment (glomerular filtration rate ‹30 mL/min/1.73 m2), contrast media of low or iso-osmolar are potentially nephrotoxic, which should keep watching them and appreciating its relationship with the contrast media induced nephropathy. It is important to recognize the clinical patient factors and the type and manner of application of the contrast medium and its relation to the contrast media induced nephropathy. In all patients, risk factors should be identified so that the dose of contrast is decreased and the necessary preventive measures are taken to prevent contrast media induced nephropathy.


REFERENCES

  1. Rao QA, Newhouse JH. Risk of nephropathy after intravenous administration of contrast material: A critical literature analysis. Radiology 2006;239:392-397.

  2. Kruskal JB, Siewert B, Anderson SW, Eisenberg RL, Sosna J. Quality initiatives managing an acute adverse event in a radiology department. Radiographics 2008;28:1237-1250.

  3. Thornton RH, Miransky J, Killen AR, Solomon SB, Brody LA. Analysis and prioritization of near-miss adverse events in a radiology department. AJR 2011;196:1120-1124.

  4. Motta-Ramírez GA, Jiménez-Martínez M, Álvarez-Flores NH. Anomalías detectadas en la provisión de servicios radiológicos y de imagen. La punta del iceberg que incluye solicitudes, consentimientos y protocolos. An Radiol Mex 2010;3:107-116.

  5. Valdés-Martínez F, Onofre-Castillo J, Valero-Castillo R, Mancilla-Serrato AA, et al. Análisis de la función renal en pacientes expuestos a medio de contraste intravenoso. An Radiol Mex 2014;13:18-22.

  6. Guía de los medios de contraste de la ESUR de 2008. http:// www.sedia.es/descargas/Medios_Contraste_ESUR70.pdf.

  7. Sinert R, Brandler E, Subramanian AR, Miller AC. Does the current definition of contrast induced acute kidney injury reflect a true clinical entity? Acad Emerg Med 2012;19:1261-1267.

  8. McDonald RJ, McDonald JS, Bida JP, Carter RE, et al. Intravenous contrast material-induced nephropathy: Causal or coincident phenomenon? Radiology 2013;267:106-118.

  9. Mehta RL, Kellum JA, Shah SV, Molitoris BA, et al. Acute kidney injury network: Report of an initiative to improve outcomes in acute kidney injury. Critical Care 2007;11:31.

  10. Katzberg RW, Newhouse JH. Intravenous contrast medium– induced nephrotoxicity: Is the medical risk really as great as we have come to believe? Radiology 2010;256:21-28.

  11. McDonald JS, McDonald RJ, Carter RE, Katzberg RW, et al. Risk of intravenous contrast material-mediated acute kidney injury: A propensity score-matched study stratified by baseline-estimated glomerular filtration rate. Radiology 2014;271:65-73.

  12. Rodríguez-Nava P, Dena-Espinoza E, Basile-Lenge R, Fuentes-García M, et al. Caracterización fisicoquímica y clínica de los medios de contraste intravasculares iodados. An Radiol Mex 2008;2:129-140.

  13. Motta-RamírezGA, Gómez del Campo LA, Castillo-Lima JA. Consentimiento informado para el uso de medios de contraste en radiología. Rev Sanid Milit Mex 2000;54:106- 110.

  14. Davenport MS, Cohan RH, Khalatbari S, Ellis JH. The challenges in assessing contrast-induced nephropathy: where are we now? AJR 2014;202:784-789.

  15. Helmes-Herrera AK, Motta-Ramírez GA, Solís-Vargas MC. Los estudios radiológicos y su consentimiento informado: consecuencias de la comunicación inadecuada. An Radiol Mex 2010;2:97-103.

  16. Geenen RW, Kingma HJ, van der Molen AJ. Contrast-induced nephropathy: pharmacology, pathophysiology and prevention. Insights Imaging 2013;4:811-820.

  17. Bui KI, Horner JD, Herts BR, Einstein DM. Intravenous iodinated contrast agents: Risks and problematic situations. Clevel Clin J Med 2007;74:361-367.

  18. Morales-Buenrostro LE, Téllez-Zenteno JF, Torre-Delgadillo A. Fisiopatología de la nefropatía por medio de contraste. Rev Invest Clin 2000;52:306-313.

  19. Gaínza FJ, Liaño-García F. Guías de actuación en el fracaso renal agudo. Sociedad Española de Nefrología (SEN) 2007;27:41-81.

  20. Rihal CS, Textor SC, Grill DE, Berger PB, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002;105:2259- 2264.

  21. Solomon R, Biguori C, Bettmann N. Selection of contrast media. Kidney Int 2006;69:39-45.

  22. Solomon R, Harold LD. Contrast-induced acute kidney injury. Circulation 2010;122:2451-2455.

  23. McDonald JS, McDonald RJ, Comin J, Williamson EE, et al. Frequency of acute kidney injury following intravenous contrast medium administration: A systematic reviewed and meta-analysis. Radiology 2013;267:119-128.

  24. Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis 2002;39:930-936.

  25. Osorio-Valerio M. Nefropatía inducida por medio de contraste endovenoso yodado. An Radiol Mex 2011;1:21-26.

  26. Gómez-Herrero H, De Arriba-Villamamor C, Buldain-Parra M, Arraiza-Sarasa M. Nefrotoxicidad por contrastes yodados en estudios de tomografía computarizada a pacientes ambulatorios diabéticos en tratamiento con metformina. An Sist Sanit Navar 2013;36:197-201.

  27. McCullough PA, Wolyn R, Rocher LL, Levin RN, O’Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997;103:368-375.

  28. Balemans CE, Reichert LJ, Van Schelven BI, Van den Brand JA, Wetzels JF. Epidemiology of contrast materialinduced nephropathy in the era of hydration. Radiology 2012;263:706-713.

  29. Duerinckx AJ. Should we screen MDCT patients for risk of CIN? Eur Radiol Suppl 2006;16:17-21.

  30. Nikolsky E, Mehran R, Lasic Z, Mintz GS, et al. Low hematocrit predicts contrast-induced nephropathy after percutaneous coronary interventions. Kidney Int 2005;67:706-713.

  31. Rosenstock JL, Guilles E, Geller AB, Panagopoulos G, et al. Impact of heart failure on the incidence of contrast-induced nephropathy in patients with chronic kidney disease. Int Urol Nephrol 2010;42:1049-1054.

  32. Traub SJ, Kellum JA, Tang A, Cataldo L, et al. Risk factors for radiocontrast nephropathy after emergency department contrast enhanced computerized tomography. Acad Emerg Med 2013;20:40-45.

  33. Moos SI, Stoker J, Nagan G, de Weijert RS, et al. Prediction of presence of kidney disease in a general patient population undergoing intravenous iodinated contrast enhanced computed tomography. Eur Radiol 2014;24:1266-1275.

  34. Mehran R, Aymong ED, Nikolsky E, Lasic Z, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 2004;44:1393- 1399.

  35. Krol AL, Dzialowski I, Roy J, Puetz V, et al. Incidence of radiocontrast nephropathy in patients undergoing acute stroke computed tomography angiography. Stroke 2007;38:2364- 2366.

  36. Brar SS. On behalf of the POSEIDON investigators. http:// clinicaltrialresults.org/Slides/TCT%202012/Brar-POSEIDON% 20TCT12%20LBCT.pdf

  37. Thimsen HS, Morcos SK. In which patients should serum creatinine be measured before iodinated contrast medium administration? Eur Radiol 2005;15:749-754.




2020     |     www.medigraphic.com